Glucagon-like peptide 1 receptor agonists are rapidly growing in popularity, with prescriptions for Ozempic and similar drugs quadrupling in less than three years, according to a September report from The Washington Post.
Glucagon-like peptide 1 receptor agonists are rapidly growing in popularity, with prescriptions for Ozempic and similar drugs quadrupling in less than three years, according to a September report from The Washington Post.